All In Biotech

Drug Trial Radar · NCT07945821

A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors

A Phase 1/2, Multicenter, Open-Label, Multicohort Study Evaluating the Safety and Efficacy of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Aug 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Coherus Oncology, Inc.Industry
Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.

Conditions

  • Solid Tumor

Interventions

  • TagmokitugDrug

    Specified dose on specified days.

  • PasritamigDrug

    Specified dose on specified days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to approximately 2.5 years
  2. Number of Participants with Dose-limiting Toxicities (DLTs)Time frame: Up to 56 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.